MSLN and mesothelioma: Survival was significantly longer for patients with mesothelioma expressing mesothelin diffusely (100% of positive cells) on the cell membrane using 5B2 (36.0 months median vs. 10.0 months with heterogeneous or no mesothelin expression; P = 0.002, Figure 7A) or MN-1 (33.0 months median vs. 9.0 months with heterogeneous or no mesothelin expression; P < 0.001, Figure 7B) antibodies.